Stocktoria
Foghorn Therapeutics Inc. FHTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-10-23
Foghorn Therapeutics Inc. statistics & valuation
Market cap$247.8M
P / S8.0×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -279.5% | -454.3% | -315.9% | -609.2% | -7637.1% |
| Net margin | -240.3% | -383.2% | -288.2% | -566.3% | -7681.6% |
| FCF margin | -278.7% | -448.2% | -349.4% | 1000.6% | -4060.9% |
| Return on assets | -37.5% | -30.5% | -34.4% | -26.9% | -19.5% |
| Return on equity | 68.5% | 190.3% | 127.5% | -97216.1% | -104.6% |
| Debt / equity | — | — | — | — | 0.00× |
| Current ratio | 2.73 | 3.73 | 4.11 | 6.37 | 9.44 |
| Revenue growth | 36.8% | -33.8% | 77.6% | 1357.8% | 206.7% |
Source: SEC EDGAR filings · CIK 0001822462 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.